Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza; Elisabeth Avall-Lundqvist; Michael J. Birrer; Rene dePont Christensen; Gitte-Bettina Nyvang; Susanne Malander; Maarit Anttila; Theresa Louise Werner; Bente Lund; Gabriel Lindahl; Sakari Hietanen; Ulla Peen; Maria Dimoula; Henrik Roed; Anja Or Knudsen; Louisa Boufercha; Synnove Staff; Anders Krog Vistisen; Line Bjorge; Johanna Unelma Maenpaa

doi:10.1200/JCO.2019.37.15suppl.5505

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza, Elisabeth Avall-Lundqvist, Michael J. Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa Louise Werner, Bente Lund, Gabriel Lindahl, Sakari Hietanen, Ulla Peen, Maria Dimoula, Henrik Roed, Anja Or Knudsen, Louisa Boufercha, Synnove Staff, Anders Krog Vistisen, Line Bjorge, Johanna Unelma Maenpaa

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	5505
Tidsskrift	Journal of Clinical Oncology
Vol/bind	37
Udgave nummer	15, Suppl.
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2019.37.15suppl.5505
Status	Udgivet - 20 maj 2019
Begivenhed	Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, USA Varighed: 31 maj 2019 → 4 jun. 2019

Konference

Konference	Annual Meeting of the American Society of Clinical Oncology (ASCO)
Land/Område	USA
By	Chicago
Periode	31/05/2019 → 04/06/2019

Adgang til dokumentet

10.1200/JCO.2019.37.15suppl.5505

https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.5505

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Mirza, M. R., Avall-Lundqvist, E., Birrer, M. J., Christensen, R. D., Nyvang, G.-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., Hietanen, S., Peen, U., Dimoula, M., Roed, H., Knudsen, A. O., Boufercha, L., Staff, S., Vistisen, A. K., Bjorge, L., & Maenpaa, J. U. (2019). Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24. Journal of Clinical Oncology, 37(15, Suppl.), Artikel 5505. https://doi.org/10.1200/JCO.2019.37.15suppl.5505

@article{f055f1139b88408891b7842ae133098a,

title = "Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.",

author = "Mirza, {Mansoor Raza} and Elisabeth Avall-Lundqvist and Birrer, {Michael J.} and Christensen, {Rene dePont} and Gitte-Bettina Nyvang and Susanne Malander and Maarit Anttila and Werner, {Theresa Louise} and Bente Lund and Gabriel Lindahl and Sakari Hietanen and Ulla Peen and Maria Dimoula and Henrik Roed and Knudsen, {Anja Or} and Louisa Boufercha and Synnove Staff and Vistisen, {Anders Krog} and Line Bjorge and Maenpaa, {Johanna Unelma}",

year = "2019",

month = may,

day = "20",

doi = "10.1200/JCO.2019.37.15suppl.5505",

language = "English",

volume = "37",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15, Suppl.",

note = "Annual Meeting of the American Society of Clinical Oncology (ASCO) ; Conference date: 31-05-2019 Through 04-06-2019",

}

Mirza, MR, Avall-Lundqvist, E, Birrer, MJ, Christensen, RD, Nyvang, G-B, Malander, S, Anttila, M, Werner, TL, Lund, B, Lindahl, G, Hietanen, S, Peen, U, Dimoula, M, Roed, H, Knudsen, AO, Boufercha, L, Staff, S, Vistisen, AK, Bjorge, L & Maenpaa, JU 2019, 'Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.', Journal of Clinical Oncology, bind 37, nr. 15, Suppl., 5505. https://doi.org/10.1200/JCO.2019.37.15suppl.5505

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24. / Mirza, Mansoor Raza; Avall-Lundqvist, Elisabeth; Birrer, Michael J. et al.
I: Journal of Clinical Oncology, Bind 37, Nr. 15, Suppl., 5505, 20.05.2019.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.

AU - Mirza, Mansoor Raza

AU - Avall-Lundqvist, Elisabeth

AU - Birrer, Michael J.

AU - Christensen, Rene dePont

AU - Nyvang, Gitte-Bettina

AU - Malander, Susanne

AU - Anttila, Maarit

AU - Werner, Theresa Louise

AU - Lund, Bente

AU - Lindahl, Gabriel

AU - Hietanen, Sakari

AU - Peen, Ulla

AU - Dimoula, Maria

AU - Roed, Henrik

AU - Knudsen, Anja Or

AU - Boufercha, Louisa

AU - Staff, Synnove

AU - Vistisen, Anders Krog

AU - Bjorge, Line

AU - Maenpaa, Johanna Unelma

PY - 2019/5/20

Y1 - 2019/5/20

U2 - 10.1200/JCO.2019.37.15suppl.5505

DO - 10.1200/JCO.2019.37.15suppl.5505

M3 - Conference abstract in journal

SN - 0732-183X

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15, Suppl.

M1 - 5505

T2 - Annual Meeting of the American Society of Clinical Oncology (ASCO)

Y2 - 31 May 2019 through 4 June 2019

ER -

Mirza MR, Avall-Lundqvist E, Birrer MJ, Christensen RD, Nyvang GB, Malander S et al. Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24. Journal of Clinical Oncology. 2019 maj 20;37(15, Suppl.):5505. doi: 10.1200/JCO.2019.37.15suppl.5505